i3 Health Podcast

Are you treating extrapulmonary neuroendocrine carcinomas based on where they start—or what they actually are? In this faculty follow-up to their i3 Health activity (Clinical Challenges in Extrapulmonary NEC: Expert Insights on Diagnosis, Treatment, and Emerging Targets), Andrew Hendifar, MD, and Danielle Hutchings, MD (Cedars-Sinai Medical Center), unpack why treating these rare, aggressive tumors according to site of origin rather than tumor lineage can compromise outcomes. They clarify crucial pathologic distinctions between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) while emphasizing the essential role of multidisciplinary collaboration in precision care. The experts also explore the novel therapeutic landscape of delta-like ligand 3 (DLL3)–targeted therapies, highlighting the promise of DLL3 T-cell engagers in extrapulmonary disease. They address ongoing diagnostic hurdles—such as standardized immunohistochemistry (IHC) expression thresholds and expanding send-out testing access—while sharing key insights on emerging clinical trials evaluating T-cell engager monotherapies and chemo-immunotherapy combinations. Claim your CME credit: https://bit.ly/488fPhK Download and review the companion Clinical Challenges in Extrapulmonary NEC Slide Deck: https://bit.ly/4w2Pni3

What if hitting prostate cancer earlier and harder is the key to delaying disease progression and sparing patients from invasive salvage therapies? In this follow-up to his i3 Health Virtual Tumor Board, Stephen Freedland, MD, Cedars-Sinai Medical Center, unpacks practice-changing data from ASCO that is actively reshaping care algorithms across the prostate cancer continuum. Dr. Freedland dives into the breakthrough TALAPRO-3 trial—exploring why talazoparib plus enzalutamide is making waves across diverse HRR alterations (including BRCA and ATM)—and analyzes how the PROTEUS trial’s 35% reduction in subsequent salvage therapies could redefine surgical planning for high-risk localized disease. Plus, get an insider's look at what’s on the horizon with PSMA PET imaging, T-cell engagers, and AR degraders. 🎓Complete the Educational Activity: bit.ly/4x2BnWf

Chronic inflammatory demyelinating polyneuropathy (CIDP) presents significant challenges in both diagnosis and long-term disease management. As consensus definitions, emerging targeted therapies, and research into serologic biomarkers evolve, how can clinicians optimize individual care algorithms? In this follow-up discussion, Karissa Gable, MD, Duke University Medical Center, breaks down recent breakthroughs in CIDP care and trial design: - Standardizing CIDP Terminology: Key updates from the new international consensus definitions paper establishing unified criteria for disease remission, stability, treatment response, and refractory disease. - The Emerging Pipeline: What’s next in therapeutic development, including FcRn antagonists (nipocalimab and batoclimab) and complement inhibitors. - Shared Decision-Making: Practical strategies for tailoring therapy selection based on patient preferences, lifestyle, comorbidities, and administration routes. - Building Confidence in CIDP Care: Applying 2021 EAN/PNS guidelines to navigate diagnosis and ongoing treatment adjustments when first-line options fall short. 💡 Complete the Educational Activity: bit.ly/4pPcVWe 👉 Access the accompanying slide deck for comprehensive guidance on CIDP detection and management: bit.ly/4pPcVWe

Frontline treatment selection for newly diagnosed multiple myeloma (NDMM) is more complex than ever. With quadruplet regimens and anti-CD38 antibodies redefining the landscape, how do you choose the right therapy for each unique patient? In this exclusive preview, Ashley Chen, PharmD, BCOP (Fred Hutchinson Cancer Center), shares actionable insights on: 🔹The Nuances of Modern Selection: Balancing comorbidities and logistical hurdles. 🔹Managing Induction Burden: Proactive strategies for steroid side effects and neuropathy. 🔹Pragmatic Dosing: Finding the most sustainable, real-world dose for frail or older patients. 📅 Save Your Spot for the Live Event! Get case-based guidance from Dr. Rahul Banerjee, Dr. Ashley Chen, and Dr. Beth Faiman. Session 1: July 8 at 6:00 pm ET: https://bit.ly/3SitVaC Session 2: July 28 at 7:00 pm ET: https://bit.ly/4oIAcZo

Think PFIC is only a pediatric disease? Think again. Progressive Familial Intrahepatic Cholestasis (PFIC) was long considered a condition exclusive to children. However, breakthroughs in genomic sequencing are revealing a hidden population: adults with "unexplained" cholestasis who are actually living with undiagnosed PFIC variants. Early identification is the difference between manageable care and irreversible liver damage. In this interview episode Dr. Aparna Goel, Stanford School of Medicine, and Dr. Laura Bull, UC San Francisco, break down the adult phenotype of PFIC and how clinicians can close the diagnostic gap. What You'll Hear In This Episode: The Adult Phenotype: Why adult cases often present as "indolent" or mild compared to the severe jaundice seen in infants. Diagnostic Red Flags: When to move beyond standard autoimmune panels and look for genetic markers. Genetic Testing 101: A comparison of targeted gene panels vs. whole exome sequencing for the most efficient diagnosis. The Power of a Name: How a specific PFIC diagnosis changes everything—from family counseling to starting life-altering IBAT inhibitors. 💡 Earn 1.5 Free CME/AAPA Credits 👉 Join the Escape Room: i3health.com/pfic

The treatment of esophagogastric cancer is undergoing a profound transformation. In this episode, Yelena Janjigian, MD (MSKCC), discusses how perioperative chemoimmunotherapy and precision biomarkers are redefining the standard of care. Key highlights include: - The Perioperative Shift: Why starting immunotherapy before surgery is achieving unprecedented pathologic responses. - Precision Testing: The essential role of MSI, PD-L1, HER2, and CLDN18.2 testing for every patient. - Avoiding Understaging: Why clinical evaluation must go beyond imaging to prevent missed therapeutic opportunities. - Multidisciplinary Success: The critical need for surgeon-oncologist communication before the first incision. Tune in to learn why "cure" is the new benchmark in localized disease and how to integrate these advances into your clinical practice today. Interested in the complete CE activity? Complete Module 1: https://bit.ly/45u106o Complete Module 2: https://bit.ly/3HtOziO

Click here to view the full CME/NCPD/CPE/AAPA activity and hear additional insights on the HER2-mutant NSCLC treatment landscape! https://i3health.com/course-information/nsclc-advances The FDA’s recent expanded approval of zongertinib marks a significant milestone in the treatment of non-small cell lung cancer (NSCLC). As the first oral human epidermal growth factor receptor 2 (HER2) inhibitor to move into the frontline setting, this therapy offers a new standard of care for patients with metastatic or unresectable non-squamous NSCLC harboring HER2 mutations. Following the approval, Beth Sandy, Thoracic Oncology Nurse Practitioner at the University of Pennsylvania, sat down to explore its clinical implications, including efficacy data, side effect management, and the potential of having a once-daily oral pill for improving patient experiences.

Hemophilia care is evolving faster than ever. Dr. Robert Sidonio, Jr., a leading expert from Children’s Healthcare of Atlanta, joins us to discuss the latest breakthroughs in research and clinical trials. From navigating new treatment options to the importance of personalized patient selection, Dr. Sidonio shares the "real-world" perspective clinicians need to stay ahead. Listen now to discover what the future holds for hemophilia management! Click here to complete the activity, Raising the Bar for Hemophilia Management, and claim your CME credit: https://bit.ly/3Ini6vj

Schizophrenia is far more than hallucinations and delusions. In this Faculty Follow-Up, Christoph U. Correll, MD—Professor of Psychiatry and Molecular Medicine at the Zucker School of Medicine at Hofstra/Northwell and Chair of Child and Adolescent Psychiatry at Charité University in Berlin—joins us to unpack the full multidimensional nature of schizophrenia. Dr. Correll explores how our understanding of positive, negative, and cognitive symptoms continues to evolve, why these domains matter for real-world functioning, and how to better identify and treat often-overlooked symptom clusters. He also highlights practical strategies for multidisciplinary collaboration, engaging patients and families in shared decision making, and integrating emerging evidence into everyday practice to optimize outcomes. To dive deeper into this topic and earn CME/NCPD/AAPA/CPE credit, view Dr. Correll’s full activity and here: https://bit.ly/3KSTtHK

Neuroendocrine tumor (NET) care is changing fast—and the pace of innovation is only accelerating. In this episode, Aman Chauhan, MD, Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF), breaks down the latest advances that are reshaping how clinicians diagnose and treat NETs. Dr. Chauhan, who recently chaired i3 Health’s CME activity Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, returns to highlight what’s new and what matters most for practice. From evolving epidemiologic insights to emerging targeted therapies and next‑generation immunotherapies, he explains how these developments are expanding options for patients and refining real‑world decision making. Whether you’re a clinician treating NETs, a trainee looking to stay current, or a listener interested in where cancer care is headed next, this conversation offers a concise, high‑yield tour of the NET landscape—and where it’s going next. Click the link to view the full activity and claim your free CME credit: bit.ly/41Qo65Y Click here to download/view the infographic: bit.ly/4bbSUmL